NCT06846398进行中（未招募）2 期
A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of BW-20805 in Adult Subjects With Hereditary Angioedema
Shanghai Argo Biopharmaceutical Co., Ltd.32 个研究点 分布在 6 个国家目标入组 25 人开始时间: 2025年2月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
- 试验地点
- 32
- 主要终点
- To determine the prophylactic effect of in HAE attack rate.
研究概览
简要总结
A Phase 2 in Adult Subjects with Hereditary Angioedema
详细描述
A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of BW-20805 in Adult Subjects with Hereditary Angioedema
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have given written informed consent and be able to comply with all study requirements.
- •Males or females 18 to 70 years of age at the time of informed consent.
- •Documented diagnosis of HAE-1/HAE-
- •At least 2 HAE attacks within the 8-week run-in period, as confirmed by an investigator based on the protocol-specified definition
- •Access to and ability to use ≥ 1 acute medication(s)
- •Female subjects must be non-pregnant;non-lactating, and either surgically sterile
- •Male subjects with WOCBP partners, dual contraception is required if no surgically sterile
排除标准
- •Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study
- •Any concomitant diagnosis of another form of chronic angioedema, such as acquired angioedema, HAE with normal C1-INH, idiopathic angioedema, or recurrent angioedema associated with urticaria
- •History or presence of carcinoma within 5 years prior to screening, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated.
- •Have undergone major surgery within 3 months prior to screening.
- •History of clinically significant arterial or venous thrombosis, or current clinically significant prothrombotic or bleeding risk
- •History of allergic reaction to an oligonucleotide or N-acetylgalactosamine
- •Prior treatment with any oligonucleotides within 6 months if single dose or 12 months if multiple doses prior to screening.
- •Exposure to another investigational drug or biological agent within 30 days or within at least 5 half-lives prior to screening.
- •With ANY of the abnormalities in clinical laboratory tests at screening and run-in period
- •Clinically significant findings on 12-lead electrocardiogram that would place the patient at risk or interfere with participation in the study at screening.
- •Positive for Human immunodeficiency virus (HIV), HBsAg, Hepatitis C or syphilis infection
- •Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to dosing.
研究组 & 干预措施
Cohort 1
Experimental
BW-20805 600 mg Q24W*2
干预措施: BW-20805 (Drug)
Cohort 2
Experimental
BW-20805 300 mg Q24W*2
干预措施: BW-20805 (Drug)
Cohort 3
Experimental
BW-20805 300 mg Q12W*2
干预措施: BW-20805 (Drug)
结局指标
主要结局
To determine the prophylactic effect of in HAE attack rate.
时间窗: from baseline to Day169
Change in time-normalized monthly (per 4 weeks) HAE attack rate from baseline to Day169
次要结局
- To evaluate the safety and tolerability of multiple doses of BW-20805.(up to 96 weeks)
研究者
研究点 (32)
Loading locations...
相似试验
进行中（未招募）
不适用
The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and AdolescentsCrohn’s DiseaseMedDRA version: 17.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-004381-24-Outside-EU/EEACB Celltech100
已完成
2 期
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)ide Analogs in Participants With Chronic Hepatitis B Virus InfectioHepatitis B, ChronicJPRN-jRCT2061210044akama Takahiro102
进行中（未招募）
1 期
A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection.Chronic Hepatitis B Virus InfectionMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-002450-81-PLJanssen-Cilag International NV102
进行中（未招募）
1 期
A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection.Chronic Hepatitis B Virus InfectionMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2021-002450-81-ESJanssen-Cilag International NV102
进行中（未招募）
1 期
A clinical trial to evaluate if apremilast is safe in children and adolescents with moderate to severe plaque psoriasis as well as assessing how apremilast is processed by the body, and to determine the appropriate dose for themModerate to severe plaque psoriasis in adolescents (ages 12 to 17 years, inclusive) and in children (ages 6 to 11 years, inclusive).MedDRA version: 18.1 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2015-003314-24-ESCelgene Corporation32